NasdaqGM:APGEBiotechs
A Look At Apogee Therapeutics (APGE) Valuation After Positive Asthma Trial Data And 2026 Pipeline Milestones
Asthma data and 2026 pipeline milestones come into focus
Apogee Therapeutics (APGE) attracted fresh attention after reporting positive interim Phase 1b data for zumilokibart in mild to moderate asthma, alongside outlining key 2026 milestones across atopic dermatitis and other inflammatory indications.
See our latest analysis for Apogee Therapeutics.
Against this backdrop, Apogee’s recent asthma update and 2026 pipeline timeline arrive after a strong 90 day share price return of 41.85% and a 1...